Severe acute hepatitis induced by alendronate [1];Hépatite aiguë sévère imputable à l'alendronate

Gastroenterologie Clinique et Biologique

Volumn 26, Issue 2, 2002, Pages 179-180

  Carrère, Christophe ^a   Duval, Jean Luc ^a   Godard, Bruno ^a   De Jaureguiberry, Jean Pierre ^b   Ciribilli, Jean Marc ^a  

^a Hôpital d'Instruction des Armées Sainte Anne   (Canada)

^b Hôpital d'Instruction des Armées Sainte Anne   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID;

ADULT; BONE DENSITY; BONE MINERAL; CHOLESTASIS; DRUG EFFICACY; DRUG TOLERABILITY; ECHOGRAPHY; FEMALE; HEPATITIS; HUMAN; LETTER; LIVER METABOLISM; LIVER NECROSIS; MAJOR CLINICAL STUDY; OSTEOPOROSIS; PAGET BONE DISEASE;

AGED; ALENDRONATE; BONE DENSITY; FEMALE; HEPATITIS, TOXIC; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 17344380266     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (6)

1. Définitions et critères d'imputation des atteintes hépatiques aiguës médicamenteuses
2. Alendronate: From laboratory to the patient: The clinical tolerability profile of alendronate
3. Dose-response study of alendronate sodium for the treatment of cancer-associated hypercalcemia
4. Alendronate treatment of the post menopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling
5. Hepatitis after alendronate
6. Liver damage due to alendronate